Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study

Abstract Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and subsequently to SB2 (double switch) in pati...

Повний опис

Бібліографічні деталі

Автори:	Stefano Mazza, Nicole Piazza O. Sed, Francesco Simone Conforti, Alberto Fascì, Alessandro Rimondi, Beatrice Marinoni, Valentina Casini, Chiara Ricci, Francesca Munari, Lorena Pirola, Pietro Invernizzi, Carlo Girelli, Guido Lupinacci, Luca Pastorelli, Flaminia Cavallaro, Luca Ferraris, Alice Colucci, Arnaldo Amato, Gian Eugenio Tontini, Maurizio Vecchi, Gionata Fiorino, Flavio Caprioli
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wiley 2022-01-01
Серія:	Clinical and Translational Science
Онлайн доступ:	https://doi.org/10.1111/cts.13131
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!